All In Biotech

Drug Trial Radar · NCT07943390

A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BRC-201 in Adult and Adolescent Patients With Acute Uncomplicated Influenza Virus Infection

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Boryung Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection. The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.

Conditions

  • Influenza

Interventions

  • BRC-201Drug

    BRC-201 (pixavir marboxil) 20 mg capsules administered orally as a single dose of 40 mg (2 capsules) for participants weighing less than 80 kg or 80 mg (4 capsules) for participants weighing 80 kg or more.

  • PlaceboDrug

    Placebo capsules matching BRC-201, administered orally as a single dose of 2 capsules for participants weighing less than 80 kg or 4 capsules for participants weighing 80 kg or more.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Alleviation of Influenza-related Symptoms (TTAS)Time frame: From Day 1 (post-dose) through Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.